

Augsburger Schriften zum Arzneimittel- und Medizinproduktrecht

herausgegeben von Prof. Dr. iur. Ulrich M. Gassner in Zusammenarbeit mit der  
Forschungsstelle für Medizinproduktrecht der Universität Augsburg

**Katarzyna Zbierska**

**Application and Importance of Supplementary  
Protection Certificates for Medicinal Products  
in the European Union**

Shaker Verlag  
Aachen 2012

## LIST OF CONTENTS

<b>1.</b>	<b>PREFACE</b>	<b>1</b>
<b>2.</b>	<b>STATISTICS ON SPCs</b>	<b>4</b>
2.1	Number of SPCs granted, expired, invalid, SPC applications filed, withdrawn or rejected	4
2.1.1	1991-2003	4
2.1.2	1991-2004	6
2.1.3	1991-2009	7
2.2	Number of SPCs granted in breakdown with respect to the character of the certificate	9
2.2.1	1991-2003	9
2.2.2	1991-2004	10
2.3	Number of SPCs in breakdown with respect to the marketing authorisation based on which SPC was issued	11
2.4	Number of SPCs in breakdown with respect to therapeutic activities	12
2.5	Number of SPC in particular years	14
2.5.1	Number of SPC applications filed in 2003	14
2.5.2	Number of SPC applications filed in 2004	15
2.5.3	Number of SPC applications filed in 2006	16
2.5.4	Number of SPC applications filed in 2007	17
2.5.5	Number of SPC applications filed in 2009	18
2.5.6	Number of SPC in new EU member states in 2004	19
2.6	Main SPC holders in particular years	20
2.6.1	Main SPC holders in 2003	20
2.6.2	Main SPC holders in 2004	21
2.6.3	Main SPC holders in 2006	22
2.6.4	Main SPC holders in 2007	23
2.6.5	Main SPC holders in 2009	25
2.7	Summary	25
<b>3.</b>	<b>ORIGINS OF AN SPC</b>	<b>27</b>
3.1	Legal situation in the EU member states prior to harmonization of laws with regard to SPC	27
3.2	Legislation process	32
3.3	Regulation 1768/92	35
3.3.1	Legal basis of the Regulation 1768/92	35

3.3.2	Territorial scope of application of the Regulation	37
3.3.3	Codification of the Regulation 1768/92	38
3.4	Amendment of Art. 63 of the European Patent Convention	40
3.5	Spanish challenge to the Regulation	45
3.5.1	“Ultra vires” argument	45
3.5.2	“Wrong legal basis” argument	48
3.6	Regulation 1610/96, its objects and main concepts	50
3.7	Regulation 1901/2006, its objects and main concepts	51
3.8	Marketing authorisation procedures	53
3.9	Summary	56
4.	<b>LEGAL CONCEPT OF AN SPC</b>	58
4.1	Introduction	58
4.2	Subject of protection under an SPC	60
4.2.1	Notion of a “basic patent”	60
4.2.2	Notion of the “product” and the “medicinal product”	64
4.2.3	Combination of active ingredients (qualitative approach) – a new product due to additives	67
4.2.4	Issue of a match between the product protected by a basic patent and a marketing authorisation	73
4.2.4.1	Scenario 1	74
4.2.4.2	Scenario 2	75
4.2.4.3	Scenarios 3-4	75
4.2.5.	Development of case law concerning match between a basic patent, the first marketing authorisation and an SPC application, with a focus on combination products	76
4.2.5.1	<i>Takeda</i> case - “identification/ express-disclosure test”	76
4.2.5.2	<i>Gilead</i> case - “clear-pointer test”	77
4.2.5.3	<i>Astellas</i> case	79
4.2.5.4	<i>Sumatriptan</i> case	81
4.2.5.5	<i>Pantoprazole I</i> case	81
4.2.5.6	<i>Medeva, Georgetown</i> cases - “explicit-basis test”	83
4.2.5.7	<i>Daiichi Sankyo, University of Queensland</i> cases	91
4.2.5.8	<i>Yeda Research</i> case	92
4.2.6	Multiphase medicinal products	94
4.2.7	Risk of infringement in case of products with the same active ingredients in common	94
4.2.8	Summary	95
4.2.9	Products differing in the proportion of impurities	97

4.2.10	Product as a result of a specific stereochemistry	100
4.2.11	Product as a result of a new preparation process	106
4.2.12	Combination of active ingredients (quantitative approach) – a new product due to a different proportion	107
4.2.13	One patent protecting many products	109
4.2.14	Second and further medical uses of the active ingredient	110
4.2.15	SPC for a medical device	112
4.2.16	Summary	119
4.3	First authorisation to place the product on the market as a medicinal product	120
4.3.1	Marketing authorisation issued in accordance with the Directive 2001/82 or Directive 2001/82	123
4.3.2	First marketing authorisation in the Community v. first authorisation in the country where the application for SPC was filed	134
4.3.3	Marketing authorisation held by a person different from patent holder(s) or his/their successor(s) in title	136
4.3.4	First authorisation as a veterinary product v. first authorisation as a medicinal product	142
4.3.5	Geographical aspect of the first marketing authorisation in the Community	146
4.3.6	Practical questions concerning the relevant marketing authorisation	152
4.3.7	First marketing authorisation and the transitional periods	155
4.3.8	Summary	158
4.4	First certificate	160
4.4.1	Original concept	160
4.4.2	Development of the original concept; interpretation of Art. 3(c) of the Regulation	161
4.4.3	Principle of uniformity; risk of market fragmentation	162
4.4.4	Doctrine of exhaustion	164
4.4.5	Art. 3(c) of the Regulation 469/2009 and Art. 3.2 of the Regulation 1610/96	165
4.4.6	Teleological interpretation	169
4.4.7	Basic patent owned by more than one entity	172
4.4.8	Summary	174
4.5	Scope of protection	175
4.5.1	General principles	175
4.5.2	Effect of an SPC	177
4.5.3	SPC and derivatives (salts, esters); the “salt problem”	178
4.5.3.1	Salt problem 2	179
4.5.3.2	Salt problem 1	183

4.5.4	Summary	188
4.6	Term of SPC protection; expiry of SPC term	190
4.6.1	Term of an SPC – historical aspects	190
4.6.2	Formula for calculating term of protection	193
4.6.3	Expiry of an SPC	197
4.6.4	“Zero”- or “negative”-term SPC	201
4.6.4.1	Model A	202
4.6.4.2	Model B	203
4.6.4.3	Model C	202
4.6.5	Extension of SPC term	212
4.6.6	Practical difficulties	215
4.6.7	Summary	221
4.7	Invalidity of an SPC	222
4.7.1	Reasons for invalidity	222
4.7.2	Non-exhaustive character of list of grounds for invalidity	227
4.7.3	Summary	233
4.8	Ownership of an SPC	234
4.9	Formal requirements	236
4.9.1	Deadline for lodging SPC application	236
4.9.2	Concurrent SPC applications	241
4.9.3	Content of SPC application	241
4.9.4	Fees	242
4.9.5	Rejection of an SPC application; grant of an SPC	244
4.9.6	Publication	246
4.9.7	Practical difficulties	247
4.9.8	Summary	248
<b>5.</b>	<b>TRANSITIONAL PERIODS IN THE REGULATION</b>	249
5.1	Transitional periods – entry of the Regulation 1768/92 into force	249
5.2	Transitional periods – enlargement of the EU	252
5.2.1.	EU enlargement on 1 May 2004	252
5.2.2	EU enlargement on 1 January 2007	256
5.3	SPC and parallel import	260
5.3.1	Specific Mechanism	263
5.3.2	Case law concerning the Specific Mechanism	273
5.4	National SPC before implementation of the Regulation	278

5.5	Summary	280
<b>6.</b>	<b>SPC AND COMPETITION LAW</b>	282
6.1	Relation between SPC and European competition law	282
6.2	Potential for abusive application	285
6.3	Conclusions from the pharmaceutical sector inquiry with respect to SPC	291
6.4	SPC and licensing	294
6.4.1	Impact of SPC on existing patents license agreements in the light of competition law	294
6.4.2	Compulsory licensing of SPC	296
6.4.3	Summary	300
<b>7.</b>	<b>SPC IN THE CONTEXT OF OTHER LEGAL PROTECTION INSTRUMENTS; ROLE OF AN SPC IN THE ENTIRE LEGAL PROTECTION SYSTEM</b>	301
7.1	General concept of data exclusivity and market exclusivity	301
7.2	Origins of data exclusivity; transitional period	306
7.3	Conditions of abridged applications	307
7.4	Legislation in force	308
7.5	The system “8+2+1”	308
7.6	Orphan exclusivity, paediatric exclusivity	312
7.7	Relations between data exclusivity, market exclusivity and an SPC	314
7.8	Summary	323
<b>8.</b>	<b>SIMILAR CONCEPT IN USA</b>	324
8.1	Status of PTE	325
8.2	Requirements	325
8.3	Term of protection	327
8.4	Product	329
8.5	Authorisation	332
8.6	Scope of protection	335
8.7	Application procedure	337
8.8	Interim extension	338
8.9	Summary	339
<b>9.</b>	<b>FINAL BALANCE</b>	340
9.1	Positives and drawbacks	340
9.2	Potential improvements	341
9.3	Perspectives of the SPC system in the EU	342
	<b>BIBLIOGRAPHY</b>	345